先声药业
Simcere

SIMCERE PHARMACEUTICAL GROUP LIMITED

2022 R&D DAY

STOCK CODE: 2096.HK

DISCLAIMER

These presentation materials have been prepared by Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (the "Company") in accordance with the prevailing economic, legal, market and other conditions and for

...atives shall not be obliged to make any revision, amendment or acknowledgement to such information. It is information in summary form and does not purport to be complete, nor does it constitute a recommendation regarding the securities of the Company (the "Securities").

The information contained in these presentation materials has not been reviewed by any regulatory authorities, and has not been independently verified. The Company does not intend to provide, and you should not rely on

...affiliates, directors, supervisors, officers, employees, agents, advisers or representatives shall make any express or implied representation, warranty or undertaking as to the accuracy, reliability, completeness, fairness...

...proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong and is subject to material change without notice. These presentation materials contain certain...

...be correct, accurate or complete. There may also be some other significant risks which have not been identified by the Company as significant risks, while the Company and its advisers or representatives may not be aware of...

...are solely responsible for assessing the business, financial condition, operating results, operating and market conditions, or prospects of the Company...

...understand and observe any applicable legal or regulatory requirements. These presentation materials shall not constitute or form part of any offer or issue of the Securities nor any solicitation or invitation for offer of purchase or subscription of the Securities. These presentation materials are provided to you for information only and shall be kept confidential and shall not be reproduced in whole or in part in any form, or distributed to any other person...

...subscription or underwriting of any Securities or structured products or any indication thereof, and no offer or solicitation has been made in respect of the purchase or subscription of any Securities.

AGENDA

01 Welcome Speech

Ren Jingsheng
Chairman of the Board & CEO

5min

02 Company Overview Strategy

Zhou Gaobo
CIO

10min

03 Pre-clinical R&D Update

04 Late-stage Oncology Pipeline

Bijoyesh Mookerjee , MD
CMO， Oncology

20min

05 Late-stage Non-oncology Pipeline

Danny Chen , PhD
SVP, neuroscience

20min

06 Strengthening BD, M&A and Investments within Global Strategy

07 Q&A - ALL

HOST : Jason Bao
Secretary of the Board

Company Overview Strategy

Zhou Gaobo
CIO

Fundamentals of our business driven by extensive unmet clinical needs in China and beyond

Forecast of global patient population in 2030: China, EU, US (10,000 people)



diseases: AD, Schizophrenia, ymia, Depressive, BD, osy, Cerebral Stroke, PD; mmune diseases: RA, AS, asis, SLE, Gout, Sjögren's rome, Atopicdermatitis, UC,

Note: CNS Dysth Epilep Autoir Psoria Syndr

Source: analysis of World Bank and Silicon Valley Bank, data of GD and CCI

Biopharma innovation flourishing in China while bottlenecks also emerging —— industry entering innovation 2.0 era

t quality of

by domestic biotech

Biopharma innovation driven by growth patient needs,

Number of IND applications in China

644

298

64%

262

18 2019 2020 2021

omestic biotechs MNC biotechs

omestic pharmacos MNC pharmacos

Intense competition and crowding limit

Clinical research programs sponsored and pharmacos in China

Note: according to clinical research statistics from IND to Phase III trials

pharmaceutical company

2021

- ENWEIDA ® approved for marketing

-2020

Innovation Center

- Sanbexin® approved for marketing
- Listed on the Hong Kong Stock Exchange

- Iremod® approved for marketing
- Established State Key Laboratory

2006-2010

- Launched the company's first innovative drug Endostar®
- Listed on the New York Stock Exchange

恩度 ENDOSTAR

必存



Innovative and competitively differentiated products contribute to 60%+ of Simcere's revenue

Share of innovative products in total revenue



Sanbexin®

The only newly approved stroke drug globally since 2015

Entered **2,400** hospitals in first year of launch

100+% growth annually, major contributor to **CNS portfolio**

ELA (Trilaciclib)

n-class comprehensive
-protective therapy

2021.11.29
NDA priority review
by NMPA

ENWEIDA (Envafolimab)

Global first subcutaneous PD-L1

2021.11.25
Approved

COSI

First-i
myelo

2,000 patients tr

Full value chain capabilities enable Simcere's innovation aspiration



Accelerating towards innovation through in-house R&D and partner collaboration

Local innovation capabilities

Innovation Center Boston

- Global clinical Development
- BD Development
- New opportunity with breakthrough potentials

Innovation Center Shanghai

Oncology & Immunology,
Pre-/clinical capability

Innovation Center Beijing

Neuroscience & Transl Sci
Clinical Dev, Registration, IP

Track record as partner of choice

Bristol Myers Squibb · G1 Therapeutics · GT innovation · JW Pharmaceutical · aeromics · Primary Peptides · Apexigen · HIGHTECHBIO

National Key Lab Nanjing

Sustained R&D investment for future growth

R&D Spending Ratio

ool



PhD/Post-Doc
MSc

employees

950 +

advanced degree

> 60 %

R&D Talent Po

Seasoned team with global vision

Sustained high quality growth driven by key innovative products

Projected share of innovative products in total revenue

Peak sales (USD)



Key developments expected in 2022

Joining the fight against COVID-19

Sanbexin®, ENWEIDA®

Innovative drugs sales

China phase III clinical trial to be completed in H1 2022

to be launched in China in 2022

Highlights

Targeting large Chinese patient population receiving [illegible] is expected to be launched in China in 2022

chemotherapy, the product has the potential of gaining huge market share and attention.

achieved annual sales of RMB 1.5 billion in its first year. The rapid clinical development of Sanbaxin

a multi-mechanism full-course therapeutic approach.

[illegible] is achieved [illegible] in the first and 2Cl inhibitor approved for clinical trial in China. The first [illegible]

in early April.

e of nearly 60 projects, with 20 projects in clinical stage,

Innovation

Simcere has formed a new drug R&D pipeline

involving 17 potential innovative drugs.

[illegible] R&D [illegible]

nd talent pool etc.

Globalization

internationalized organization and

Preclinical Drug R&D

Tang Renhong, PhD

EVP

Preclinical R&D Strategy and Drug Discovery Engines

Patient-Centric Drug Discovery Strategy

Growing Portfolio with Strong long-term Potential



ecules to the Clinical in less than 5 years

- Research Delivered 17 Mole

Proprietary platforms support diversified drug modalities



Simcere Creative platform of Protein Engineering



Adopting AI in Drug Discovery

- Focus on the application on early stage drug discovery, such as hit generation optimization
- Establishing data science infrastructure and capability internally
- Collaborating with external partner for agile development





Project X – Our Path to the Future

ocusing on exploring and creating

…to attract and unite a group of young talents in life science and fo

s with either high treatment needs or

10 directions/technologies
breakthrough potential

drug discovery

fill the gap during the transformation of research hypothesis to therapeutics development

Building the true innovative research engine

Diseases-Specific Strategies and key Assets

Autoimmunity, Neuroscience

Oncology

matological malignancy

Building Depth on prioritized tumor types: Lung, Breast, GI, Female reproductive, He





- Simultaneously targeting two checkpoints for improved immune activation

> 50% Tumor growth inhibition achieved in PD-L1 blocker insensitive model

SIM0237: PD-L1/IL15v Bifunctional Fusion Protein

Best-in-Class potential with Improved tumor control and low safety risk



Significant Tumor Growth Inhibition



NCI-H292-hPBMC xenograft model

Rationale:

- Blocking PD-1/PD-L1 signaling and deliver IL-15 directly to TME for fully activation of CD8 T cells
- Fine tune IL-15 pharmacological profile through protein engineering

SIM0217: First-in-Class RAD51 inhibitor

Significant advantages on efficacy, safety , developability compared to current leading competitor

In Vivo Efficacy

rel human
s with poor prognosis

- RAD51 plays a central role in the homologous recombination pathway



Superior In Vitro Activity And I



Overexpressed in cancer
malignancies correlate
tumors

- Multiple combination potential with chemotherapy and other DDR pathway targeting therapeutics

Broad combination opportunities for multiple tumor types

Combo with Docetaxel in



Combo with ATRi in

Combo with WEE1i in



Pancreatic Cancer



vot role in mismatch repair (MMR) with synthetic lethal potential to microsatellite instability (MSI)

ly disclosed inhibitor yet

fication of Hit compound through virtual lib screening supported by machine learning algorithm

- Target plays a piv
- Current no public
- Successful identi

Enzyme Inhibition

Induction of DNA Damage



Tumor Growth Inhibition



Autoimmunity



- Re-establish Treg/Teffs balance

- Minimizing the systemic side-effects

SIM0278： IL-2 mutein specifically Promote Treg Function

Differentiation through protein engineering



Strong Treg activation
extreme low Tcon stimulation

Great anti-inflammation
Prevent GvHD occurrence

- Avoid interaction with Il -2Rα
- Iincreased IL-2Rαβγ/IL-2Rβγ window
- Treg-biased binding

Ab-Steroid conjugate for Th2 suppression

Significant decrease of IgE production and inflammatory cell infiltration bring great histological improvement

Neuroscience

Expand Sanbexin® to Hemorrhagic Stroke

Collagenase-induced intracerebral hemorrhage Model

Reduce Cerebral Edema



iorate Dyskinesia



Subarachnoid Hemorrhage Model

Protect Blood-Brain Barrier Integrity



Improve Neuron Function



Amel

SIM0417: Inhibitor for COVID-19 Pandemic

Oral 3CL protease inhibitor jointly developed with Shanghai Institute of Materia Medica

2021.11.17 Collaboration with SIMM

2022.03.28

2022.04.10 IND Approval

2022 Q3 Phase 1 FIH

Phase 2/3 trials



viral activity against wild-
strain, inhibit viral replication in lung
cantly improve lung damage caused

rmacokinetic Properties SIM0417
tic properties *in vivo*, its lung tissue

[illegible]

No genotoxicity.

- **Good Antiviral Activity** great antiv
  type, delta and Omicron
  and brain tissue, signific
  by the virus.
- **Excellent *in vivo* Pha**
  has good pharmacokine

[illegible]

Expected submissions in 2022

Q1 Q2 Q3 Q4

SIM0272 PRMT5 IND
China

SIM0323 CD80/IL2v IND
China

SIM0237 PD-L1/IL15v IND
US

SIM0237 PD-L1/IL15v IND
China

SIM0417 3CL (COVID19) IND
China

TIGIT/PVRIG IND
US

PSD-95 IND
China

SIM0271 MAT2A IND
China

SIM0348 TIGIT/PVRIG IND
China

SIM0278 IL-2mu-Fc IND
US

Oncology Autoimmunity Neuroscience

先声药业 Simcere

Key Takeaways for Today

1 Patient-centered principle is core of our drug R&D efforts



Improve TA-focused strategy through deeper understanding of disease biology 3

Quick and agile execution of high potential assets for clinical validation 4



Late-stage Oncology Pipeline

Oncology Clinical R&D Strategy

Focus on innovation to maximize impact on patients



nts in China

Clinical value-oriented medicines to provide greater efficacy for cancer patie

Simcere anti-tumor products approved for

Estimated incident rates of new cancers (China)

Endostar® (Endostatin), ENWEIDA® (Envafolimab),

Lung cancer

Trilaciclib,SIM0201(NTRK), SIM0235(TNFR2)

Breast cancer Trilaciclib, SIM0270(SERD BM)

14.58 Colorectal cancer

11.34 Cervix cancer

Gastric cancer

Colorectal cancer 21.65

Esophageal cancer 16.81

Prostate cancer 6.72

Oncology Pipeline Layout

Maximize existing, and accelerate new medicines and combinations



Differentiated Targets and Indications

Providing novel medicines for cancer patients with greater efficacy

Key Project Introduction

Progress in Clinical Trials

Trilaciclib: a CDK4/6 inhibitor that provides prophylactic bone marrow protection

Protects hematopoietic stem/progenitor cells (HSPCs) from chemotherapy and enhance the immune system through

Prevent multiple adverse events of myelosuppression through multilineage bone marrow protection[1-3]

Mitigate neutropenia

avoid administration delay and



Enhance immune response and protect immune function

- Change the proliferation kinetics and co
cell subsets in tumors to enhance the nu

mposition of T
umber and

Pipeline-in-a-Molecule Opportunity Beyond ES-SCLC Launch



in 1Q 2023 expected to include results for myeloprotection and Objective Response Rate (ORR) endpoints
t in 2H 2023 expected to include interim results for Overall Survival (OS)

Trilaciclib: accelerating the indication process in China

tage SCLC

1-3L chemotherapy (N=92)

n s enrolled.

dging, primary analysis completed, PK and

overseas countries

primary endpoint (DSN in the first cycle).

ing application submitted to China NMPA in November

2021, Priority Review was granted, expected to be approved in 2022

*DSN; duration of severe neutropenia

Only FDA-approved therapy that proactively delivers multilineage myeloprotection to extensive s patients being treated with chemotherapy

2021/2/12

On 12 February 2021, FDA fully approved **COSELA™ (Trilaciclib)** for bone marrow protection in ES-SCLC patients, which is **the world's first and only** bone marrow protection therapy that can reduce the incidence of chemotherapy-induced myelosuppression

TRACES study in China:

Phase III trial for ES-SCLC treated with

- The 1st part: safety lead-in and PK bri
- benefit trend consistent with those in c
- Th 2nd part: pla ebo-controlled, rand
- Conditional market

2021/11/29

Submission of Conditional Marketing

Trilaciclib: PRESERVE trials

Phase-III global clinical trial for bone-marrow-protection in CRC patients treated with FOLFOXIRI & Bevacizumab (N=296)

- **Primary Endpoint : Duration of severe neutropenia in cycle 1 and occurrence of severe neutropenia during Induction**
- **FPI worldwide: 16 October 2020**
- **FPI in China: 24 September 2021**

PRESERVE 2 : TNBC (N=170)

Phase III global clinical trial of survival impro

Trilaciclib showed strong OS improvement in the TNBC randomized controlled phase II trial.

In July 2021, TNBC indication was granted Fast Track designation by the F

Endostar® New Indication: malignant [illegible] thoracoabdominal effusions

Early studies have shown that Endostar® also has a positive therapeutic effect on malignant thoracoabdomin

effusions[1]

nparison in 3 groups (number of cases, %)

compared with cisplatin, * P<0.05



ORR com

statin injection
l NSCLC in China

Endostar® is a recombinant human endo
approved for first-line treatment of advanced

l Oncology, 2017

.Shukui Qin, etc. Chinese Clinica

Endostar® New Indication: COREMAP study

To address the urgent need of patients with malignant thoracoabdominal effusions

ors whose expected survival is
tion of abdominal distension caused
high as 29% (meta analysis).

the incidence of intracavitary
19 and is estimated to increase to

COREMAP ： Endostar® for treatment of malignant thoracoabdominal effusions, phase III

CHINA

Intra-pleural injection of recombinant human endostatin/placebo with cisplatin in treatment of malignant thoracoabdominal effusions: a multicenter, randomized,

- Among patients with incurable tum
  longer than two weeks, the proport
  by ascites and other reasons is as
- According to Frost & Sullivan data,
  malignancy reached 707,900 in 20
  756,900 by 2030.

Tumors causing malignant thoracoabdominal effusions



Tumors causing malignant thoracoabdominal effusions



- **Recruitment: 105 subjects enrolled as of March 30,2022**
- **Interim results analysis expected in H2 2022**
- **FPI: 28 July 2021**

Shukui Qin, etc. Chinese Clinical Oncology, 2017

great potential[2]

- Clinical trials underway in other forms of brain cancer beyond GBM: DIPG, primary CNS lymphoma, brain metastases.
- Potential to combine with chemotherapy, radiotherapy and targeted drugs (e.g., EGFR inhibitors).
- Potential to target non-brain cancers: Breast cancer, NSCLC, CRC, endometrial cancer, GIST, pancreatic cancer, RCC, TCC, HNSCCs, GBM, leukemia, melanoma, and NHL

blastoma (GBM)
000 cases
nnum worldwide

- The main treatment drug is **Temozolomide**
- China's annual market size for GBM is about **2B yuan**
- Temozolomide **almost ineffective for 65%** of the patients (those with unmethylated MGMT status)

Gliob
133,0
per a

BM indication, Orphan Drug designation was granted

- For the GI

Envafolimab

First PD-L1 Antibody Approved For Subcutaneous Injection

- Envafolimab has a good safety profile as a single agent
- Envafolimab phase II trial for advanced MSI-H/dMMR solid tumor showed it



2020 and approved in November 2021

2020 CSCO	N	ORR	DCR	12moPFS	12mo OS
Total	65	43.1%	61.5%	43.7%	72.9%
Treatment failure after Advanced 3 drugs					
Treatment failure after 2 drugs					
Other solid tumors	20	40.0%	65.0%	52.6%	75.0%

- Novel humanized dAb against PDL1
- Low immunogenicity
- Mutant Fc to eliminate ADCC/CDC activity
- Stable

1.2020 CSCO

Envafolimab and Anti-angiogenic Combinations

Envafolimab + Sovalcitzumab

Phase II trial of Envafolimab combination therapy in solid tumor patients

Exploration of PD-1+VEGF products

IND approval: 24 August 2021, FPI: 22 December 2021

Continue to explore other possible indications of the combination therapy

- Using Simcere Diagnostics TSO500 Kit, benchmarked against FoundationOne® CDx.

Preclinical	IND	Phase I	Phase II	Phase III	NDA

TMB-H advanced cancer (mono, 2L+)

EC (mono and combo with lenvatinib, 2L+)

NSCLC, HCC, RCC (combo with lenvatinib)

HCC, CRC, NSCLC (combo with BD0801)

Clinical study led by collaborator 3D Medicines

SIM0235： Humanized anti-TNFR2 monoclonal antibody

New targets for tumor immunity



loring the development potential of single agents in solid tumors and

FR2[1,2,3] on the cell surface:

f TNFR2 by endogenous TNF, it ffects TNFR2-mediated immunosuppression and tumor cell roliferation.

ntibody-dependent cell-mediated cytotoxicity (ADCC) mediated y Fc terminal has a direct killing effect on immunosuppressive ells, including tumor cells expressing TNFR2, regulatory T cells Tregs) and bone marrow-derived suppressor cells (MDSCs).

TNFR2 Humanized Animal Model: Single Drug Efficacy



Animal Model Data: Combination with Anti-PD-L1 Antibody



It can specifically recognize TN

• By blocking the activation o a p

• A b c (T

1.Williams GS et al., Oncotarget. 2016;2.Vanamee E et al., Trends in Molecular Medicine.

SIM0270: BBB permeable, tumor tissue-enriched, [illegible] oral active compound

Name	R&D company	Clinical phase	Oral	BBB permeability
Fulvestrant	AstraZeneca	Approved SERD compound Annual sales exceeding 1 billion US dollars		
SIM0270	先声药业	Phase I		



CORE ADVANTAGES

SIM0270 showed superior in vivo and in vitro efficacy to Fulvestrant, comparable to those of GDC-9545, a leading compound in clinical practice.

- SIM0270 showed a significantly better brain-blood ratio than alternative compounds and [illegible]

mor growth combined with
vivo

ER+ brain in situ model



Inhibit ER+ tu
Palbociclib in

[illegible] significantly inhibited tumor growth with CDK4/6 inhibitor Palbociclib in ER+ breast cancer model.

- Phase I clinical trial started in 2021 and phase III expected in 2024

Milestones 2021-2022



ncer, TNBC: triple
gen receptor

Note: SCLC: small-cell lung cancer, CRC: colorectal ca
negative breast cancer, OS: overall survival, ER: estrog

Operational Excellence Driving Simcere's Purpose and R&D Vision



Operational Excellence— New Asset Development

Globalization to Further Extend Asset Value

Providing Today's Patients with Medicines of the Future

Clinical value-oriented

Innovative pipelines

Operational Excellence

Global R&D Strategy

Late-stage
Non-oncology Pipeline

Overall Strategy

Focus on targets and disease of high unmet needs

Central Nervous System (CNS)

- Sanbexin®/Sanbexin sublingual indication expansions in China and globally
- Develop novel FIC compounds alone and in combination to further improve

Autoimmune

- Breakthrough therapy to address the limitations of current treatment
- Focus on rheumatology and

Summary

CNS/Autoimmune clinical strategies and highlights – clinical value and differentiation

Non-oncology Pipeline

CNS, Autoimmune, and the disease areas that have significant clinical needs in the future



Key Project Introduction

CNS

CNS Clinical Focus

Subsegments of nervous system disease

Neurological drug R&D success	Few domestic	Both China-unique and

China's Stroke Treatments Still Have Huge Challenges

Rate

Large Number Patients And Low Thrombolytic



About 30% of ischemic stroke patients missed the thrombolysis treatment window due to hospitalization later than 6h from onset.

Proportion of patients receiving rt-PA within 3 hours of onset[2]	China	US
	18.3%	83.6%

Average thrombolytic rate

Ischemic Stroke Patients 5-year Recurrence Rate[3-4]	41%

Number of Discharged Patients with Ischemic and Hemorrhagic Stroke in China 2005

(10000 person)



069-3
ease report 2020

1. China Health Statistics Yearbook 2020
2. DOI: 10.3760/cma.j.cn112137-20210416-00914.
3. The lancet global health 10.1016/S2214-109X(20)300
4. China cardiovascular health and dis

48 clinical centers across the country participated in the trial, including ~1200 subjects, and the data were

with

Primary efficacy endpoint: Proportion of patients

mRS score ≤ 1 on day 90 of treatment

~1.81, P = 0.0004

OR:1.42, 95%CI:1.12~

Sanbexin®: TASTE II Ischemic Stroke Reperfusion Study

Planning to enroll over 130 subjects, across nearly 80 clinical centers in China

- A phase IV study to evaluate the efficacy and neurological recovery of Sanbexin combined with early endovascular recanalization therapy in patients with Acute

TASTE-2

After vascular recanalization, Sanbexin can directly enter the ischemic site to promote the recovery of ischemic damaged brain tissue

Protect the brain tissue from re-injury caused by ischemia-reperfusion injury

The efficacy of new neuroprotective agent edaravone dexborneol combined with alteplase on AIS

...cantly improve neurological function in stroke patients.

Sanbexin®: Hemorrhagic Stroke Indication

Preclinical study

Animal experiments showed that Sanbexin® could significantly improve the prognosis of cerebral hemorrhage.

- Sanbexin® administration two hours after the onset of collagenase-induced ICH could significantly relieve the cerebral edema caused by hemorrhagic stroke

the treatment of cerebral hemorrhage

The trial will be launched in the end of 2022.

N≈300



Sanbexin Sublingual Tablet

To further expand the effectiveness of Sanbexin in stroke treatment and recovery



Sanbexin Sublingual Tablet

f participants with mRS≤1

Phase III clinical study in the treatment of acute ischemic stroke

Primary endpoint: proportion of
on day90 of treatment

ndomized
1:1
ble-blinded
llel control

Sanbexin Sublingual tablet

placing a tablet under the tongue to obtain the sublingual administration, every 12±1 h, for 14 days (28 times) in a consecutive manner

Placebo Sublingual tablet

chieve database

Ran
doub
paral

Whole course management of stroke (N=914)

- **June 28, 2021, the first case of the subject's delivery**
- **December 31, 2021, achieving the enrollment of 519 subjects, exceeding expectations**
- **March 12, 2022, 783 subjects were enrolled**
- **Interim analysis expected in 2022H1, and complete**

recruitment of all subjects, and ac
lock

[redacted]

Phase I clinical trial in China

- IND approval: April 2021
- FIH: December 2021
- Phase I co[illegible]

Chinese population


combination of multiple mechanisms
01 Reduce neuroinflammation

SIM0408: Targeting A Key Catalytic Enzyme in Neurotoxic Aβ Aggregate Formation

QPCT oral small molecule inhibitor



Key Project Introduction

Autoimmune

Iremod® New Indication: Sjogren's Syndrome

The efficacy and safety for RA have been verified for over 10 years

score, hyperglobulinemia and ESR of the patients were significantly lower than those at baseline

The world's first and China's only approved iguratimod (IGU) compound

The only domestically developed

ARD approved in
st decade

small-molecule DM
the pas

anguo team. EULAR. Ann Rheum Dis, 2019, 78 (suppl 2): A1696 (No.AB0465)
://doi.org/10.3389/fphar.2021.621208

Lizha
https

Iremod® New Indic



The pathogenesis h

Lack of effective clinical drugs

In April 2020, Iremod entered the "China Standard for the Diagnosis and Treatment of Primary Sjögren's Syndrome"

Clinical Progress and Plan

April 28, 2021 EPI

Completion of Phase II clinical results readout and initiation of Phase III clinical studies

LNK01001： Selective Jak1 Inhibitor

March 18, 2022, Simcere entered into a collaboration agreement with Lynk Pharmaceuticals, to obtain the exclusive commercialization interest of LNK01001 for rheumatoid arthritis (RA) and Ankylosing spondylitis (AS) indications in China. Lynk Pharmaceuticals will be responsible for the clinical development of LNK01001.

LYNK PHARMACEUTICALS

RA AS

Phase 1 PK and PD summary:

- **SAD:** PK parameters increase proportionally in the range of 6 mg to 84 mg along with the dose.Exposure in vivo to LNK01001 AUC and Cmax are linearly kinetic.
- **MAD:** AUCs with multiple administrations on D1 & D7: basically consistent; basically, no accumulation in the body
- No dose-related incidence of adverse events
- **FE:** AUC shows no significant change with fasting or eating state; postp

Phase I studies in healthy subjects demonstrats good safety and tolera

- No TEAE above >2 or
- No SAE;
- No death-causing TEA

Milestones Expected in 2022

Iremod® (Sjogren's syndrome)

Result summary of phase II; Regulatory communication before phase III

417(3CL)

Orally Administered SSD8432 COVID-19
Treatment, phase I & phase II/III
Phase I, CSR
Phase II/III, FPI

SIM0408(QPCT)

(international multicenter)
FPI

Sanbexin®(Cerebral hemorrhage)

Hemorrhagic stroke as a newly added indication of

SIM04

Sanbexin Sublingual Tablet

Y-2 for AIS treatment, phase III
FPI, LPI

Sanbexin®(Reperfusion)

Sanbexin® combined with reperfusion for AIS treatment, phase IV
Achieve the enrollment goal

SIM0335

CKBA for treatment of mild to moderate

SIM0307（AQP4）

Acute severe ischemic stroke complicated with cerebral edema, phase I, CSR

FPI, LPI

SIM0278

IL-2 for treatment of systemic lupus Erythematosus
FDA IND

Strengthening BD, M&A and Investments within a Global Strategy

Kevin Oliver , PhD
SVP, Global H[illegible]

Simcere's BD/M&A Team has high credibility, is diverse and has a deep reputation in the industry

18、2019、2020

ve experience

Professional (ASAP) Excellence Awards

30

FTE

250+

acquisitions integrated collectiv

201

TRANSACTIONS



Kevin Oliver
SVP Global Head of BD&L

MERCK NOVARTIS Alcon

Yuehua Cong
ED Head of BD&L EU

F-star POLYTHERICS

Yves McMullen
Head of US Transactions and Global Invest.

Gaobo Zhou.
CIO, Head of BD&L AP

McKinsey & Company

Michael Bayewitch
ED, US AP Transaction

teva

S&E

LEGAL

AM

Catherine Abbadie
Global Head of CNS S&E

Matthias Hoss
Global Head of Autoimmune

Markus Decker
Global Head, Oncology S&E

Roche

Ian Liu
Head of Legal & Gov't Affairs, US EU

FOSUN 复星 BRFAS BOSTON BIOMEDICS

Mark Coffin
VP Global Alliance Management

先声药业

BD is geographically established to become 'Partner of Choice'

Search & Evaluation

Transaction

Alliance & Integration

Post-Investment

Global c[illegible]centered in Boston, will focus on six key, global operational strategies

Platforms as innovation driver

Global clinical center of excellence

High return of investment

perational
xcellence

Open business development: Clinical/Academic/Pharma

Academic partnership to drive innovation

People, Integrity, Trust and proven Capabilities are critical to being ‘Partner of Choice’



Simcere values its existing 35+ alliances and I R positions

ALPHAMAB ONCOLOGY

ercialization of LNK01001, a highly

cancer therapy, in China

Collaboration to develop and

Collaborate to introduce

Co-development of Paxalisib ,a

Comme

vivoryon

eate as the founder

Partner with a Nobel laure

Avilex pharma

NeuronDawn

Collaborate to develop Sanhavin®

Collaboration on AVILY-144 an

Collaborate withthe second largest pharmaceutical company in Korea to develop new drug for gout in China

Shanghai Institute of Materia Medica
Chinese Academy of Sciences

Partnership to develop novel antiviral drugs for COVID-19

Bristol Myers Squibb

Co-development of Orencia® (Abatacept), a blockbuster drug for RA in China

Strategic partner
Exclusive commercialization of Olmetec Plus® (Olmesartan medoxomil, Hydrochlorothiazide) in China

CORMORANT ASSET

HEALTHCARE

Strategically driven BD: In-licensing interests in Oncology

drug screening

ug targets with First-in-class and/or Best-in-

) late preclinical) with innovative

First-in-class

Modality agnostic

nering with academia –
obal licensing rights and an

&A

Small molecule and biologics

Focus on high unmet need indications that are TOP10 prevalent tumor types in China

Focus on assets with clinical PoC in relevant indications

Novel drug classes/modalities (RNA therapeutics, Tetra-specific IgG mAb, etc.)

Novel ex-vivo functional screening platforms (Novel types of SL interactions)

Flexible partnership models (In-licensing/Co-dev, R&D collaborations, JV & Equity Investment, M&A)

Innovative modalities

High-throughput structure-based (Challenging Targets)

Novel dru

Earlier stage assets

Novel platform capability part relationships that lead to gl engine to feed the pipeline

Late / commercial stage M&

Strategically-driven BD: In-licensing interests in CNS and Autoimmune

Autoimmune

Indications with immune-mediated pathology and high unmet need in China

Current focus on rheumatology and dermatology

General

Focus on high unmet medical need in China

Later-stage assets with clinical PoC in relevant indications

Earlier stage assets (≥ late preclinical) with innovative mechanisms need to have potential to deliver highly

CNS

Neurology: Focus on Stro

Neurod
Parkins

Pain, S

Psychia
Schizop

Flexible partnership mo
licensing/Co-dev, R&D

Investment opportu

ke

legeneration:
on's, Alzheimer's

leep

try: Depression, Anxiety,
hrenia

dels (In-

nities)

Exclusive License Agreement for Trilaciclib in Greater China



Exclusive License Agreement for small molecule, PQ912, and biologic in Greater China

2020

2021

2022

2020.06.29
Established collabration

2021.12.14
IND submission

2022.2.25
IND approval

2022.5
Phase II (MRCT) - FPI

2022.7



Phase 2 N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease.

Best efficacy among available clinical opportunities

patients

3DMed Alphamab Exclusive License Agreement for Envafolimab in Mainland China



Simcere as Partner of Choice in China… with global ambitions



Q & A

ATTENDEES







HOST :

SIMCERE PHARMACEUTICAL GROUP LIMITED

STOCK CODE: 2096.HK

IR CONTACTS

Tel: +86(25)8556 6366 Email: ir@simcere.com

Postal Address: Board Office, Simcere Pharmaceutical Group Limited 699-18 Xuanwu Avenue, Xuanwu District, Nanjing, Jiangsu